

@article {518,
	title = {Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses},
	journal = {Expert Rev Anti Infect Ther},
	volume = {12},
	number = {10},
	year = {2014},
	note = {1744-8336 Florescu, Diana F Keck, Megan A Journal Article England Expert Rev Anti Infect Ther. 2014 Oct;12(10):1171-8. doi: 10.1586/14787210.2014.948847. Epub 2014 Aug 13.},
	pages = {1171-8},
	type = {Journal Article},
	abstract = {CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.},
	keywords = {BK virus Brincidofovir Cmx001 JC virus adenovirus cytomegalovirus dsDNA virus molluscum orthopoxvirus vaccinia virus},
	issn = {1478-7210},
	doi = {10.1586/14787210.2014.948847},
	author = {Florescu, D. F. and Keck, M. A.}
}
